Hemab Therapeutics (COAG) vs Inhibrx Biosciences (INBX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Hemab Therapeutics is the larger company by market cap ($1.44 billion vs $1.37 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | COAG | INBX |
|---|---|---|
| Share price | $30.89 | $92.76 |
| Market cap | $1.44B | $1.37B |
| 1-day change | +7.63% | -0.64% |
| YTD return | — | +18.18% |
| 1-year return | — | +178.69% |
| EPS (TTM) | $-4.33 | $-8.88 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $55.42 | $155.29 |
| 52-week low | $23.00 | $28.16 |
| Distance from 52-week high | -44.26% | -40.27% |
| Analyst consensus | none | none |
| Avg. price target upside | +98.12% | +187.48% |
| Average volume | 453.97K | 291.93K |
| Shares outstanding | 46.71M | 14.72M |
| Employees | 59 | 109 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Hemab Therapeutics
COAG stock →Hemab Therapeutics Holdings, Inc. operates as a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience in United States of America and Denmark.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 59 employees
About Inhibrx Biosciences
INBX stock →Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates include INBRX-109, which is in phase 1, a tetravalent therapeutic candidate targeting death-receptor 5 to treat unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head non-small cell lung cancer cell carcinoma, gastric or gastroesophageal junction adenocarcinoma, renal cell carcinoma, and urothelial cell carcinoma.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 109 employees
COAG vs INBX FAQ
Which is bigger, Hemab Therapeutics or Inhibrx Biosciences?
Hemab Therapeutics (COAG) is larger, with a market capitalization of $1.44B compared with $1.37B for Inhibrx Biosciences (INBX).
Are Hemab Therapeutics and Inhibrx Biosciences in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.